All data are based on the daily closing price as of May 28, 2025
o
OBI Pharma
4174.TWO
1.13 USD
-0.02
-1.74%
Overview
Last close
1.13 usd
Market cap
297.85M usd
52 week high
2.84 usd
52 week low
1.13 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
132.4489
Price/Book Value
2.744
Enterprise Value
238.46M usd
EV/Revenue
104.814
EV/EBITDA
-12.3211
Key financials
Revenue TTM
2.28M usd
Gross Profit TTM
-2.22M usd
EBITDA TTM
-71.76M usd
Earnings per Share
-0.32 usd
Dividend
N/A usd
Total assets
147.31M usd
Net debt
N/A usd
About
OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of solid tumors; OBI-902 and OBI-904 that are in preclinical stage for the treatment of solid tumors; BsADC which is in discovery stage for the treatment of solid tumors. It also engages in investing and trading; and manufacture and wholesale of western pharmaceuticals, as well as research and development of biotechnology. OBI Pharma, Inc. was founded in 2002 and is headquartered in Taipei, Taiwan.